The American Cancer Society announced new guidelines on Thursday that reverse its 2010 position, urging routine PSA blood tests for all men at average risk between ages 50 and 69. This shift prioritizes early detection over the previous advice to leave testing decisions entirely to individual discretion after a physician consultation. The update relies on evidence showing that screening saves lives, while improved case management techniques now mitigate the harms of overdiagnosis and overtreatment that plagued earlier protocols. For high-risk groups, specifically Black men and those with a strong family history, the recommendation is even stronger: yearly PSA screening starting at age 45. I view this as a necessary correction because prostate cancer remains the second leading cause of cancer death in US men, with nearly 334,000 estimated diagnoses and over 36,320 deaths expected in 2026 alone.
Guardrails Against Overtreatment
The new guidance introduces strict procedural steps to prevent unnecessary invasive procedures. A PSA result is defined as high if it reaches 3 ng/mL or higher for men under 70, or 6.5 ng/mL or higher for those 70 and up. If the initial test is high, the ACS recommends repeating the test before taking any next steps. Only if repeat testing remains elevated should men proceed to a prostate MRI or a validated biomarker test to assess their actual risk. Biopsies are reserved for cases with a very high suspicion of cancer, such as an extremely high PSA result. This staged approach aims to reduce the number of patients undergoing biopsies for slow-growing tumors that may never cause harm in a lifetime.
James Eastham, chief of urology at Memorial Sloan Kettering Cancer Center, notes that most US lab reports list values under 4.0 ng/mL as normal, but he argues the threshold "really should be under 3." He believes this clarification will help primary care physicians refer patients for further evaluation earlier than they currently do. William Dahut, the ACS chief scientific officer, explained that including both MRIs and biomarkers provides flexibility for patients who cannot easily obtain an MRI scan. However, he noted that an MRI would still be recommended prior to biopsy if a biomarker test comes back abnormal. The guidelines do not specify which biomarker is superior, as researchers intend to look more closely at which options best predict aggressive cancer.
Individualized Decisions and Active Surveillance
For men diagnosed with low-risk prostate cancer, active surveillance should be the initial management strategy rather than immediate treatment. This approach acknowledges that many cancers will never grow or cause harm, while avoiding the risks of erectile dysfunction and urinary incontinence associated with surgery or radiation. Dr. Shanthi Sivendran, interim chief patient officer for the ACS, stated that catching aggressive cancers with a simple PSA test "opens the door to highly effective treatments that protect your future." Meanwhile, lower-risk findings can be safely managed through careful monitoring.
Screening decisions become individualized starting at age 70, as the balance of benefit and harm is less clear for older men. Testing should stop after age 80 or for men not expected to live another 10 years. Despite these updates, the U.S. Preventive Service Task Force has not changed its guidelines since new evidence became available in 2025. That panel continues to recommend against routine population-wide screening, favoring individualized decision-making instead. Since the Task Force determines which preventive services insurers must cover, this divergence creates a complex landscape for patients seeking coverage. Eddie Baynes, a 56-year-old survivor and advocate, says the new guidelines "hit the nail on the head" regarding the need for frequent testing. His own diagnosis came only after a fraternity organized a screening event when he was 52, proving that earlier routine checks could have saved him from advanced stage presentation.
